

Clinical trials of extended prophylaxis

TrialResults-center www.trialresultscenter.org

1 thrombosis prevention

Trial	Treatments	Patients	Trials design and methods
extended prophylaxis vs standard prophylaxis			
PENTHIFRAPLUS (Eriksson) , 2003 n=656 follow-up: 19-23 days	25-31 days of fondaparinux 2.5-mg once-daily versus 6-8 days of fondaparinux 2.5-mg once-daily	patients undergoing hip fracture surgery	Parallel groups double blind
Lausen , 1998 n=58/60 follow-up: 28 days	Tinzaparin 3500 UI/qd sc for 28 days started in preop versus Tinzaparin 3500 UI/qd + GES for 1 week started in preop	>18 years, open major abdominal surgery and non cardiac thoracic surgery of >1hour duration.	Parallel groups Open, blinded evaluation
ENOXACAN II (Bergqvist) , 2002 n=253/248 follow-up: 3 months	Enoxaparin 40 mg UI/qd sc for 25-31 days started in preop versus Enoxaparin 40 mg IU/qd sc for 6 to 10 days (GES optional) started in preop	>40 years, open major abdominal oncologic elective surgery of >45 minutes duration (includes gynecological surgery)	Parallel groups double blind
FAME (Rasmussen) , 2006 n=205/222 follow-up: 3 months	Dalteparin 5000 UI/qd SC for 28 days started in preop versus Dalteparin 5000 UI/qd SC for 7 days + GES started in preop	>18 years, major abdominal surgery of >1 hour duration	Parallel groups Open, blinded evaluation

More details and results :

- antithrombotics for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q37>
- antithrombotics for thrombosis prevention in hip Fracture at <http://www.trialresultscenter.org/go-Q40>
- antithrombotics for thrombosis prevention in abdominal surgery at <http://www.trialresultscenter.org/go-Q96>
- pentasaccharide for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q188>
- pentasaccharide for thrombosis prevention in all type of patients at <http://www.trialresultscenter.org/go-Q396>

References

PENTHIFRAPLUS (Eriksson), 2003:

Eriksson BI, Lassen MR Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. *Arch Intern Med* 2003 Jun 9;163:1337-42 [[12796070](#)]

Lausen, 1998:

Lausen I, Jensen R, Jorgensen LN, Rasmussen MS, Lyng KM, Andersen M, Raaschou HO, Wille-Jrgensen P Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. *Eur J Surg* 1998;164:657-63 [[9728784](#)]

ENOXACAN II (Bergqvist), 2002:

Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. *N Engl J Med* 2002;346:975-80 [[11919306](#)]

FAME (Rasmussen), 2006:

Rasmussen MS, Jorgensen LN, Wille-Jrgensen P, Nielsen JD, Horn A, Mohn AC, Smød L, Olsen B Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. *J Thromb Haemost* 2006;4:2384-90 [[16881934](#)]